Uptrend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Oct 7 · above the Ichimoku cloud · RSI 87 (overbought) · MACD above its signal
| 0.1500 | 52-week high | +288.60% |
| 0.0400 | Previous week high | +3.63% |
| 0.0386 | R3 (classic) | +0.00% |
| 0.0386 | R2 (classic) | +0.00% |
| 0.0386 | R1 (classic) | +0.00% |
| 0.0386 | Pivot | +0.00% |
| 0.0386 | S1 (classic) | +0.00% |
| 0.0386 | S2 (classic) | +0.00% |
| 0.0386 | S3 (classic) | +0.00% |
| 0.0386 | Previous day high | +0.00% |
| 0.0386 | Previous day low | +0.00% |
| 0.0386 | Price now | |
| 0.0110 | Previous week low | −71.50% |
| 0.0110 | Previous month high | −71.50% |
| 0.000100 | Previous month low | −99.74% |
| 0.000100 | 52-week low | −99.74% |
None of the 29 investors followed here reported a position in TBIO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TBIO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for TBIO.
No analyst coverage for this instrument.
Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. It has license agreement with Regeneron Pharmaceuticals, Inc. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
No recent headlines.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.0 | 7.8 | -7.3 | 7.8 | -3.6 | -98.1 | 10.0 | -9.1 | -90.0 | 38500.0 | −22.8% | ||
| 2025 | -8.2 | -10.2 | -10.6 | 86.3 | -90.9 | 500.0 | -92.7 | -45.5 | 0.0 | 0.0 | 75.0 | 138.1 | −87.5% |
| 2024 | -17.0 | 68.7 | -21.2 | -18.0 | -37.2 | -10.5 | 7.4 | -12.8 | 12.0 | -64.5 | -55.9 | -33.3 | −94.4% |
| 2023 | 53.3 | -2.7 | 73.2 | -16.5 | -38.2 | -1.3 | -1.3 | -16.7 | -20.0 | -29.7 | -42.7 | -4.7 | −66.8% |
| 2022 | -27.4 | 30.1 | -47.4 | -31.1 | 7.6 | -54.8 | 6.1 | 0.5 | -13.5 | -2.4 | -10.5 | -17.2 | −88.9% |
| 2021 | -28.2 | -17.9 | -14.2 | -17.0 | -26.0 | 57.9 | −50.9% |
TimeframesUp on the hourly and daily, down on the monthly, mixed on the weekly.
over a rising 21 EMA, 21 over 50
over a rising 21 EMA, 21 over 50
bouncing over the 21 EMA
under a falling 21 EMA, 21 under 50